Morphic Holding, Inc. (MORF)
| Market Cap | 2.09B |
| Revenue (ttm) | 42.62M |
| Net Income (ttm) | -49.54M |
| Shares Out | 33.53M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $54.59 |
| Previous Close | $57.99 |
| Change ($) | -3.40 |
| Change (%) | -5.86% |
| Day's Open | 57.94 |
| Day's Range | 53.75 - 57.94 |
| Day's Volume | 67,311 |
| 52-Week Range | 22.69 - 93.00 |
Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data were shared at the Congress of European Crohn'...
MORF-057 well tolerated across all phase 1 cohorts
Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021...
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t...
Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chron...
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -6.78% and -45.58%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Expanded research and development collaboration with Janssen for third integrin program
Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This experimental biotech has more than tripled investors' money over the past 12 months.
WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious c...
The company announced a proposed public offering of common stock.
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious c...
A series of positive news is helping the biopharmaceutical company start the week on a strong note.
Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma ...
Little-known MORF stock is rocketing higher after Morphic Holdings shared positive interim data from a Phase 1 clinical trial. The post MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today app...
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -54.05% and -26.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MORF-057 well tolerated in all dose cohorts
Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057
Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial Call to discuss financial and operational res...
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chro...
New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets New program demonstrates breadth of MInT platform with the inclusion of activating ...
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president ...
As of late, it has definitely been a great time to be an investor in Morphic Holding (MORF).
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of s...
Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021
- Data validat e physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α 4 β 7 integrin - -MORF-057, inhibitor of α 4 β 7 integrin, in development to treat inf...
First o rally available integrin inhibitor from MInT Platform to enter the clinic MORF-057, inhibitor o f α 4 β 7 integrin , in development to treat i nflammatory bowel disease Phase 1 p...
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment o...
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious c...
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 13.33% and 37.38%, respectively, for the quarter ended June 2020.
Company’s first IND accepted by FDA for MORF-057 in IBD Phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment ...
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious c...
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate
Morphic Holding Inc. (NASDAQ:MORF) is one of five fledgling biotechnology companies cited for their potential to develop a drug that generates more than $1 billion in sales, according to an article publ...
WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...
Morphic Holding, Inc. (NASDAQ: MORF) made its public debut Thursday morning, opening at $18 after being priced at $15 per share.
About MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also deve... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol MORF |
Financial Performance
In 2020, MORF's revenue was $44.95 million, an increase of 164.74% compared to the previous year's $16.98 million. Losses were -$45.00 million, 3.86% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for MORF stock is "Strong Buy." The 12-month stock price forecast is 100.50, which is an increase of 84.10% from the latest price.